"Technology Platform",please contact our team.
Langhua Pharmaceutical always adheres to the concept of sustainable manufacturing, providing clients with green, low-carbon, and sustainable commercial production services. Leveraging its team advantages and project experience, Langhua has established a Green Chemistry Technology Platform. This platform integrates advanced synthesis technology methods such as biocatalysis, continuous flow process, metal catalysis, asymmetric catalysis, photochemistry and electrochemistry. By developing efficient, green, and competitive synthesis processes for active pharmaceutical ingredients (APIs) and intermediates with these above advanced technology, Langhua continuously creates value for its clients.
Enzymatic synthesis, a biotransformation approach distinct from traditional chemical synthesis, has been widely used in the pharmaceutical industry due to its multifaceted advantages, including high efficiency, specificity, cost-effectiveness, and environmental friendliness. Langhua leverages Viva Biotech's exceptional strengths in protein structure analysis and design, and protein fermentation to establish an enzymatic synthesis platform. This platform offers clients services including high-throughput enzyme screening, directed evolution of enzymes, development and commercial production of enzymatic synthesis processes, quality control and regulatory submission of enzymatic synthesis processes.
The development of various enzymatic catalysis processes in CDMO orders have been successfully completed, involving esterases, ester hydrolases, ketone reductases (KRED), nitrile hydrolases (NIT), transaminase, lipases, chymotrypsin, acylase, oxidase ene reductase (ERED), olefin reductases, imine reductases, amino dehydrogenases, etc. An enzymatic synthesis process of a chiral ester has been developed with an esterase for an anti-COVID-19 drug project, of which the commercial production will be proceeded in the second half of the year.
Ketoreductase screening for the asymmetric reduction of ketone compounds(The annual output of 30MT has been achieved)
Amine transaminase screening for the asymmetric reductive amination to produce chiral amines(It is expected to achieve an annual output of 20MT)
Acylase screening for the enantioselective hydrolysis of N-acetyl compounds(It is expected to achieve an annual output of 40MT)
Recycling of the immobilized enzyme in enzymatic process (Retention efficiency of the immobilized enzyme after recycling three times )
Langhua Pharmaceutical's continuous flow process platform is equipped with a variety of modular equipment, including different kinds of pumps, gas or liquid mass flow controllers, (MFC), mixers, coil reactors made of stainless steel or PFA, microchannel reactors made of silicon carbide (SiC), packed bed reactors (PBR) , continuous stirred tank reactors (CSTR), back pressure valves (BPR), gas liquid separators (LGS), temperature control units (TCU), etc. Based on the process needs, those equipment could be flexibly assembled into a experiment apparatus for development and optimization of continuous flow process in lab. With automatic hydrogenator, Langhua could screen the catalysis and reaction conditions efficiently for hydrogenation. Additionally, the platform includes the commercial-scale microchannel continuous flow reactor with the production capacity of thousands of tons per annum, which could meet the larger-scale production needs.
Langhua has successfully completed continuous flow process development for organolithium reaction, oxidation, diazotization, azide reaction, nitration, hydrogenation, etc, of which the apparatus flux capability could reach 1-50 kg per day. Langhua could provide service in the design of continuous process routes, continuous flow process development, reactor design, and the commercial production implementation of continuous flow process.
Flux in lab: 20kg per day
Flux in lab: 15kg per day
Flux in lab: 30kg per day
Catalysts have been widely used in coupling reactions and asymmetric synthesis. To enhance the efficiency of route exploration and condition optimization, Langhua Pharmaceutical has established a catalyst and ligand screening platform. This platform offers services to clients, thereby saving time and cost in process development.
A professional team of nearly 20 members, most of whom have studied in renowned research groups of metal or small molecule catalysis in China.
Several core technical staff have over 10 years of research and development experience in the field of transition metal catalysis.
The Shanghai R&D center has a nearly 200 m² catalyst and ligand screening laboratory, equipped with glove boxes and high-throughput screening equipment.
Metal Catalyst and Ligand Library:
Includes nearly 10 core metals and nearly 100 ligands.
Organocatalyst Library:
Includes various kinds of chiral organocatalysts such as chiral prolines, cinchona alkaloids, chiral thioureas, and chiral phosphoric acids.
Chiral Auxiliary and Reagent Library:
Includes natural chiral pool, Evans auxiliaries, chiral sulfonamides, etc.